Secondary Logo

Journal Logo

Institutional members access full text with Ovid®

Spinal cord stimulation versus conventional medical management for neuropathic pain: A multicentre randomised controlled trial in patients with failed back surgery syndrome

Kumar, Krishnaa,*; Taylor, Rod S.b; Jacques, Linec; Eldabe, Samd; Meglio, Marioe; Molet, Joanf; Thomson, Simong; O’Callaghan, Jimh; Eisenberg, Eloni; Milbouw, Germainj; Buchser, Erick; Fortini, Gianpaolol; Richardson, Jonathanm; North, Richard B.n

doi: 10.1016/j.pain.2007.07.028
Research papers
Buy
SDC

Patients with neuropathic pain secondary to failed back surgery syndrome (FBSS) typically experience persistent pain, disability, and reduced quality of life. We hypothesised that spinal cord stimulation (SCS) is an effective therapy in addition to conventional medical management (CMM) in this patient population. We randomised 100 FBSS patients with predominant leg pain of neuropathic radicular origin to receive spinal cord stimulation plus conventional medical management (SCS group) or conventional medical management alone (CMM group) for at least 6 months. The primary outcome was the proportion of patients achieving 50% or more pain relief in the legs. Secondary outcomes were improvement in back and leg pain, health-related quality of life, functional capacity, use of pain medication and non-drug pain treatment, level of patient satisfaction, and incidence of complications and adverse effects. Crossover after the 6-months visit was permitted, and all patients were followed up to 1 year. In the intention-to-treat analysis at 6 months, 24 SCS patients (48%) and 4 CMM patients (9%) (p < 0.001) achieved the primary outcome. Compared with the CMM group, the SCS group experienced improved leg and back pain relief, quality of life, and functional capacity, as well as greater treatment satisfaction (p ≤ 0.05 for all comparisons). Between 6 and 12 months, 5 SCS patients crossed to CMM, and 32 CMM patients crossed to SCS. At 12 months, 27 SCS patients (32%) had experienced device-related complications. In selected patients with FBSS, SCS provides better pain relief and improves health-related quality of life and functional capacity compared with CMM alone.

aDepartment of Neurosurgery, Regina General Hospital, 1440 14th Avenue, Regina, Sask., Canada S4P OW5

bPeninsula Medical School, University of Exeter, UK

cDepartment of Neurosurgery, Montreal Neurological Institute and Hospital, Montreal, Canada

dDepartment of Pain and Anaesthesia, James Cook University Hospital, Middlesbrough, UK

eDepartment of Functional Neurosurgery, Gemelli Catholic University Hospital, Rome, Italy

fDepartment of Neurosurgery, Santa Creu i Sant Pau Hospital, Barcelona, Spain

gPain Clinic, Basildon and Thurrock University Hospitals, Basildon, UK

hPain Clinic, Axxon Pain Medicine, Brisbane, Australia

iPain Relief Unit, Rambam Medical Center, Haifa, Israel

jNeurosurgery, Namur Regional Hospital, Namur, Belgium

kPain Clinic, Morges Hospital, Morges, Switzerland

lPain Clinic, Varese Regional Hospital and Macchi Foundation, Varese, Italy

mDepartment of Pain and Anesthesia, Bradford Hospitals, Bradford, UK

nDepartment of Neurosurgery, The Johns Hopkins University School of Medicine, Baltimore, MD, USA

*Corresponding author. Tel.: +1 306 781 6154; fax: +1 306 781 6153.

E-mail: krishna.kumar@rqhealth.ca

E-mail: krishnakumar9@hotmail.com

Submitted November 28, 2006; received in revised form July 29, 2007; accepted July 30, 2007.

© 2007 Lippincott Williams & Wilkins, Inc.
You currently do not have access to this article

To access this article:

Note: If your society membership provides full-access, you may need to login on your society website